Twelve potential fibrosis markers to differentiate mild liver fibrosis from cirrhosis in patients infected with chronic hepatitis C genotype 1

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 30, Issue 6, 2011, Pages 761-766

  Andersen, E S ^a   Ruhwald, M ^a   Moessner, B ^b   Christensen, P B ^b   Andersen, O ^a   Eugen Olsen, J ^a   Weis, N ^a,c  

^a Mental Health Services CPH   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CXCL9 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INSULIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NERVE GROWTH FACTOR; PLASMINOGEN ACTIVATOR; SCATTER FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; ELASTOGRAPHY; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER CIRRHOSIS; LIVER FIBROSIS; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC;

ADULT; BIOLOGICAL MARKERS; CYTOKINES; ELASTICITY IMAGING TECHNIQUES; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED;

EID: 79956153117     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-010-1149-y     Document Type: Article

References (32)

1. World Health Organization (WHO) (2000) Hepatitis C fact sheet. Available online at: https://apps.who.int/inf-fs/en/fact164.html
2. Strader DB, Wright T, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases (2004) AASLD Practice Guideline: diagnosis, management, and treatment of hepatitis C. Hepatology 39:1147-1171
3. Van Thiel DH, Gavaler JS, Wright H, Tzakis A (1993) Liver biopsy. Its safety and complications as seen at a liver transplant center. Transplantation 55:1087-1090
4. McGill DB, Rakela J, Zinsmeister AR, Ott BJ (1990) A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology 99:396-400
5. Ganne-Carrié N, Ziol M, de Lédinghen V, Douvin C, Marcellin P, Castéra L et al (2006) Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology 44:1511-1517 (Pubitemid 44953656)
6. Foucher J, Chanteloup E, Vergniol J, Castéra L, Le Bail B, Adhoute X et al (2006) Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 55:403-408 (Pubitemid 43268281)
7. Friedrich-Rust M, Ong M-F, Martens S, Sarrazin C, Bojunga J, Zeuzem S et al (2008) Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 134:960-974
8. Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F et al (2005) Noninvasive assessment of liver fibrosis by measurement of stiffness in patientswith chronic hepatitis C.Hepatology 41:48-54
9. Zeremski M, Petrovic LM, Talal AH (2007) The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection. J Viral Hepat 14:675-687 (Pubitemid 47414927)
10. Neuman MG, Benhamou JP, Marcellin P, Valla D, Malkiewicz IM, Katz GG et al (2007) Cytokine - chemokine and apoptotic signatures in patients with hepatitis C. Transl Res 149:126-136
11. Asselah T, Bièche I, Laurendeau I, Paradis V, Vidaud D, Degott C et al (2005) Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C. Gastroenterology 129:2064-2075 (Pubitemid 41772981)
12. Zeremski M, Dimova R, Brown Q, Jacobson IM, Markatou M, Talal AH (2009) Peripheral CXCR3-associated chemokines as biomarkers of fibrosis in chronic hepatitis C virus infection. J Infect Dis 200:1774-1780
13. Moura AS, Carmo RA, Teixeira AL, Leite VHR, Rocha MOC (2010) Soluble inflammatory markers as predictors of liver histological changes in patients with chronic hepatitis C virus infection. Eur J Clin Microbiol Infect Dis 29:1153-1161
14. Hanley JA, McNeil BJ (1983) A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148:839-843 (Pubitemid 13033817)
15. Mühlbauer M, Bosserhoff AK, Hartmann A, Thasler WE, Weiss TS, Herfarth H et al (2003) A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology 125:1085-1093 (Pubitemid 37193455)
16. Hellier S, Frodsham AJ, Hennig BJ, Klenerman P, Knapp S, Ramaley P et al (2003) Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. Hepatology 38:1468-1476 (Pubitemid 37466973)
17. Neuman MG, Benhamou JP, Bourliere M, Ibrahim A, Malkiewicz I, Asselah T et al (2002) Serum tumour necrosis factor-alpha and transforming growth factor-beta levels in chronic hepatitis C patients are immunomodulated by therapy. Cytokine 17:108-117
18. Zylberberg H, Rimaniol AC, Pol S, Masson A, De Groote D, Berthelot P et al (1999) Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity. J Hepatol 30:185-191 (Pubitemid 29071178)
19. Neuman MG, Benhamou JP, Malkiewicz IM, Ibrahim A, Valla DC, Martinot-Peignoux M et al (2002) Kinetics of serum cytokines reflect changes in the severity of chronic hepatitis C presenting minimal fibrosis. J Viral Hepat 9:134-140 (Pubitemid 36002477)
20. Ren Y, Poon RT, Tsui HT, Chen WH, Li Z, Lau C et Al (2003) Interleukin-8 serum levels in patients with hepatocellular carcinoma: correlations with clinicopathological features and prognosis. Clin Cancer Res 9:5996-6001 (Pubitemid 38018086)
21. Akiba J, Yano H, Ogasawara S, Higaki K, Kojiro M (2001) Expression and function of interleukin-8 in human hepatocellular carcinoma. Int J Oncol 18:257-264
22. Yamagami H, Moriyama M, Tanaka N, Arakawa Y (2001) Detection of serum and intrahepatic human hepatocyte growth factor in patients with type C liver diseases. Intervirology 44:36-42 (Pubitemid 32172942)
23. Eugen-Olsen J, Andersen O, Linneberg A, Ladelund S, Hansen TW, Langkilde A et al (2010) Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med 268:296-308
24. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS et al (2003) A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38:518-526 (Pubitemid 36919874)
25. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T et al (2001) Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 357:1069-1075 (Pubitemid 32322537)
26. Forns X, Ampurdanès S, Llovet JM, Aponte J, Quintó L, Martínez-Bauer E et al (2002) Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 36:986-992
27. Sagir A, Erhardt A, Schmitt M, Häussinger D (2008) Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage. Hepatology 47:592-595 (Pubitemid 351280727)
28. Arena U, Vizzutti F, Corti G, Ambu S, Stasi C, Bresci S et al (2008) Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology 47:380-384 (Pubitemid 351280705)
29. Reiberger T, Aberle JH, Kundi M, Kohrgruber N, Rieger A, Gangl A et al (2008) IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIV-HCV coinfection. Antivir Ther 13:969-976
30. Falconer K, Askarieh G, Weis N, Hellstrand K, Alaeus A, Lagging M (2010) IP-10 predicts the first phase decline of HCV RNA and overall viral response to therapy in patients co-infected with chronic hepatitis C virus infection and HIV. Scand J Infect Dis 42:896-901
31. Romero AI, Lagging M, Westin J, Dhillon AP, Dustin LB, Pawlotsky J-M et al (2006) Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis 194:895-903 (Pubitemid 44454074)
32. Lagging M, Romero AI, Westin J, Norkrans G, Dhillon AP, Pawlotsky J-P et al (2006) IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology 44:1617-1625 (Pubitemid 44953667)